Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$0.00$0.00— vs Q1 2020 Net Income-$3.13M-$3.13MN/M vs Q1 2020 EPS Diluted-$0.07-$0.07N/M vs Q1 2020 Operating Income-$3,121,800N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,806,700— ended Jun 30, 2020 · filed Aug 13, 2020 · 44 d after period end